Analysts Set Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) Price Target at $28.00

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) has earned a consensus rating of “Moderate Buy” from the eight ratings firms that are covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and six have issued a buy recommendation on the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $28.00.

KMTS has been the subject of a number of research reports. BTIG Research assumed coverage on shares of Kestra Medical Technologies in a research report on Tuesday, November 18th. They issued a “buy” rating and a $32.00 price target for the company. Weiss Ratings reissued a “sell (d)” rating on shares of Kestra Medical Technologies in a report on Wednesday, October 8th. Finally, Wall Street Zen downgraded Kestra Medical Technologies from a “hold” rating to a “sell” rating in a research note on Sunday, September 28th.

Institutional Trading of Kestra Medical Technologies

Several large investors have recently bought and sold shares of the company. Quarry LP purchased a new position in shares of Kestra Medical Technologies during the 1st quarter worth approximately $33,000. China Universal Asset Management Co. Ltd. acquired a new position in shares of Kestra Medical Technologies in the 3rd quarter valued at $48,000. Police & Firemen s Retirement System of New Jersey purchased a new stake in Kestra Medical Technologies during the second quarter valued at about $54,000. BNP Paribas Financial Markets increased its position in Kestra Medical Technologies by 148.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 2,738 shares of the company’s stock worth $65,000 after purchasing an additional 1,638 shares in the last quarter. Finally, Brown Brothers Harriman & Co. increased its position in shares of Kestra Medical Technologies by 26.8% in the third quarter. Brown Brothers Harriman & Co. now owns 3,104 shares of the company’s stock worth $74,000 after acquiring an additional 656 shares in the last quarter.

Kestra Medical Technologies Price Performance

Shares of KMTS opened at $24.53 on Friday. The firm has a market capitalization of $1.26 billion and a price-to-earnings ratio of -9.62. The company has a current ratio of 6.84, a quick ratio of 6.84 and a debt-to-equity ratio of 0.23. The firm’s fifty day simple moving average is $25.48 and its 200-day simple moving average is $20.71. Kestra Medical Technologies has a twelve month low of $13.25 and a twelve month high of $30.00.

Kestra Medical Technologies (NASDAQ:KMTS) last released its quarterly earnings data on Thursday, September 11th. The company reported ($0.50) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.66) by $0.16. The business had revenue of $19.37 million for the quarter, compared to analyst estimates of $17.68 million.

About Kestra Medical Technologies

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution.